Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 May 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2023 Results from nested case-control study , Using data from NCT01988571; comparing breast/lymphoma patients that experienced CTRCD to breast/lymphoma patients matched on age, race, and ANTH dose without CTRCD (controls). presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation
07 Nov 2022 Results of secondary analysis; evaluating how socioeconomic status or in terms of social determinants of health, economic stability, serve as a protective factor regarding LVEF decline during treatment with doxorubicin for breast cancer and lymphoma, presented at the American Heart Association Scientific Sessions 2022
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com